Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era

Bevacizumab (BZM) and temozolomide (TMZ) have been shown to be beneficial in the treatment of patients with glioblastoma. We sought evidence for the benefit of BZM in the general patient population at large. The Surveillance, Epidemiology, and End Results SEER database was queried for patients diagn...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachtel, Mitchell S, Yang, Shengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101757/
https://www.ncbi.nlm.nih.gov/pubmed/24610705
http://dx.doi.org/10.1002/cam4.213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101757/
https://www.ncbi.nlm.nih.gov/pubmed/24610705
http://dx.doi.org/10.1002/cam4.213

Ejemplares similares